Adjuvant therapy for renal cell carcinoma

Abstract

Recent advances in the treatment of metastatic renal cell carcinoma expose a gap in the treatment of less advanced, localized disease. Tyrosine kinase inhibitors, which revolutionized the treatment of metastatic disease, have not provided a similar survival benefit in the adjuvant setting and currently only sunitinib is approved by the Food and Drug Administration for adjuvant treatment in patients with high-risk of recurrence based on S-TRAC disease-free survival data. The advent of immune checkpoint inhibitors has offered a fresh hope in the field of adjuvant treatment after encouraging results are seen with combination of immune checkpoint inhibitors as well as with targeted therapy in the metastatic setting. Several studies are investigating these combinations in the adjuvant setting, and it is hoped that they will bring about a better outcome for a largely unmet need in kidney cancer treatment.

Keywords

Localized renal cell carcinoma / adjuvant / immunotherapy / tyrosine kinase inhibitors / prognosis / clinical trials / predictive model / risk stratification

References

[1] Frank I,Cheville JC,Weaver AL.An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score.J Urol2002;168:2395-400

[2] Parker WP,Frank I.Application of the stage, size, grade, and necrosis (SSIGN) score for clear cell renal cell carcinoma in contemporary patients.Eur Urol2017;71:665-73 PMCID:PMC5536178

[3] Zisman A,Dorey F.Improved prognostication of renal cell carcinoma using an integrated staging system.J Clin Oncol2001;19:1649-57

[4] Kattan MW,Motzer RJ,Russo P.A postoperative prognostic nomogram for renal cell carcinoma.J Urol2001;166:63-7

[5] Leibovich BC,Cheville JC.Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.Cancer2003;97:1663-71

[6] Pizzocaro G,Colavita M.Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study.J Clin Oncol2001;19:425-31

[7] Messing EM,Wilding G.Eastern Cooperative Oncology Group/Intergroup trialPhase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.J Clin Oncol2003;21:1214-22

[8] Passalacqua R,Buti S.POLAR-01 Trial InvestigatorsAdjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC).J Immunother2014;37:440-7

[9] Chamie K,Klöpfer P.Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: the ARISER randomized clinical trial.JAMA Oncol2017;3:913-20 PMCID:PMC5824229

[10] Choueiri TK.Targeting the HIF2-VEGF axis in renal cell carcinoma.Nat Med2020;26:1519-30

[11] Rini BI.Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma.J Clin Oncol2005;23:1028-43

[12] Almeida DV,Soares A.Latin America Cooperative Oncology Group - Genitourinary (LACOG-GU)Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).J Clin Oncol2019;37:4579

[13] Motzer RJ,Tomczak P.Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.N Engl J Med2007;356:115-24

[14] Choueiri TK,Halabi S.Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update.Eur J Cancer2018;94:115-25 PMCID:PMC6057479

[15] Sternberg CN,Mardiak J.Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.J Clin Oncol2010;28:1061-8

[16] Hutson TE,Stus VP.Axitinib versus sorafenib in first-line metastatic renal cell carcinoma: overall survival from a randomized phase III trial.Clin Genitourin Cancer2017;15:72-6

[17] Haas NB,Uzzo RG.Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.Lancet2016;387:2008-16 PMCID:PMC4878938

[18] Motzer RJ,Patard JJ.Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results.Eur Urol2018;73:62-8 PMCID:PMC6684251

[19] Motzer RJ,Donskov F.PROTECT investigatorsRandomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma.J Clin Oncol2017;35:3916-23 PMCID:PMC6018511

[20] Gross-Goupil M,Eto M.Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.Ann Oncol2018;29:2371-8 PMCID:PMC6311952

[21] Eisen T,Oza B.Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the SORCE randomized phase III intergroup trial.J Clin Oncol2020;38:4064-75 PMCID:PMC7768344

[22] Gul A.Adjuvant therapy in renal cell carcinoma.Cancer2019;125:2935-44

[23] Larkin J,Gonzalez R.Five-year survival with combined nivolumab and ipilimumab in advanced melanoma.N Engl J Med2019;381:1535-46

[24] Shen M,Xie Q.Association between PD-L1 expression and the prognosis and clinicopathologic features of renal cell carcinoma: a systematic review and meta-analysis.Urol Int2020;104:533-41

[25] Choueiri TK,Park SH.Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: randomized, double-blind, phase III KEYNOTE-564 study.J Clin Oncol2021;39:LBA5

[26] Uzzo R,Rini BI.A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010).J Clin Oncol2017;35:TPS4598

[27] Bex A,Tomita Y.A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high-risk of relapse after radical or partial nephrectomy (CheckMate 914).J Clin Oncol2020;38:TPS5099

[28] Renal adjuvant multiple arm randomised trial (RAMPART). Available from: https://clinicaltrials.gov/ct2/show/NCT03288532. [Last accessed on 7 Jul 2021]

[29] Haas NB,Allaf ME.PROSPER: phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).J Clin Oncol2020;38:TPS5101

[30] S0931, everolimus in treating patients with kidney cancer who have undergone surgery (S0931). Available from: https://clinicaltrials.gov/ct2/show/NCT01120249 [Last accessed on 7 Jul 2021]

[31] Buller DM.Improving patient selection for adjuvant therapy in high-risk renal cell carcinoma.Ann Transl Med2019;7:S104 PMCID:PMC6685884

[32] George DJ,Staehler M.Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: exploratory pharmacogenomic analysis.Clin Cancer Res2019;25:1165-73 PMCID:PMC6669904